Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glasdegib in AML and High-Risk MDS
NCT01546038Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2012
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of glasdegib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (6 arms), sponsored by Pfizer. Primary endpoints: Dose-limiting Toxicities at Cycle 1, Complete Response at 4 years and 1 more. Started Jun 2012; status: completed.
02
Drugs
glasdegib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01546038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01546038.